866-997-4948(US-Canada Toll Free)

Osteosarcoma Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Oncology

No. of Pages : 115 Pages


Osteosarcoma Pipeline Review, H2 2012


Global Markets Directs, 'Osteosarcoma Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Osteosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteosarcoma. Osteosarcoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Osteosarcoma.
  • A review of the Osteosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Osteosarcoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Osteosarcoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Osteosarcoma Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Osteosarcoma 11
Osteosarcoma Therapeutics under Development by Companies 13
Osteosarcoma Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Osteosarcoma Therapeutics Products under Development by Companies 22
Osteosarcoma Therapeutics Products under Investigation by Universities/Institutes 23
Companies Involved in Osteosarcoma Therapeutics Development 25
Merck & Co., Inc. 25
ZIOPHARM Oncology, Inc. 26
Advaxis, Inc. 27
Oncolytics Biotech Inc. 28
Simcere Pharmaceutical Group 29
Med Discovery SA 30
Hawthorn Pharmaceuticals, Inc. 31
Epeius Biotechnologies Corporation 32
Osteosarcoma Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 40
MDRG-01 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
cereolysin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ADXS-HER2 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
SCH-717454 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BMTP-11 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Rexin-G - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Thiotepa + Stem Cell Transplantation - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
vincristine sulfate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Bevacizumab + Cisplatin + Doxorubicin + Methotrexate + Ifosfamide + Etoposide - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Cyclophosphamide + Sirolimus - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
genetically modified T cells - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Reolysin + Cisplatin + Radiation Therapy - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
temsirolimus - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cisplatin + Doxorubicin + Methotrexate + Pamidronate Disodium - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Filgrastim + Cisplatin + Doxorubicin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
trabectedin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Cisplatin + Doxorubicin + Etoposide + Ifosfamide + Methotrexate - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
PEG-interferon Alfa-2b + Cisplatin + Doxorubicin + Methotrexate - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Zoledronic Acid + Adriamycin + Cisplatinum + Ifosfamide - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
zoledronic acid - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Methotrexate + Adrimycin + Cisplatin + Ifosfamide - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Methotrexate + Adrimycin + Cisplatin - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
AYRPVSRNI + IFA - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
AYRPVSRNI + IFA + Interferon Alpha - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
methotrexate - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Temsirolimus + Valproic Acid - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Filgrastim + Cisplatin + Dexrazoxane + Doxorubicin + Leucovorin + Methotrexate - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Filgrastim + Cisplatin + Dexrazoxane + Doxorubicin + Leucovorin + Methotrexate - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Filgrastim + Ifosfamide + Peripheral Blood Stem Cell Transplantation + Samarium Sm 153 Lexidronam Pentasodium - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 81
Filgrastim + Ifosfamide + Peripheral Blood Stem Cell Transplantation + Samarium Sm 153 Lexidronam Pentasodium - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 83
Trimetrexate + Leucovorin - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
pazopanib hydrochloride - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Methotrexate + Cisplatin + Doxorubicine - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 87
Cisplatin + Doxorubicin + Methotrexate - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 89
Adriamycin + Cisplatinum + Ifosfamide - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Docetaxel + Gemcitabine + Filgrastim + Pegfilgrastim - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
sargramostim - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
everolimus - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
haw mAb-11 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Sirolimus + Celecoxib + Etoposide + Cyclophosphamide - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
RO4929097 + Dexamethasone - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
palifosfamide + etoposide + carboplatin - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Endostar + Methotrexate + Cisplatin + Pirarubicin + Ifosfamide - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Dexrazoxane + Doxorubicin + Cisplatin + Methotrexate + Ifosfamide + Etoposide - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 102
Osteosarcoma Therapeutics Drug Profile Updates 103
Osteosarcoma Therapeutics Discontinued Products 108
Osteosarcoma Therapeutics - Dormant Products 109
Osteosarcoma Product Development Milestones 112
Featured News & Press Releases 112
Jun 24, 2011: PCI Biotech Announces Main Results Of Full Phase I/II Study Of Amphinex 112
Oct 12, 2009: Clinical Remissions In Three Otherwise Intractable Cancers Signal The Progress Of Targeted Genetic Medicine 113
May 12, 2009: Oncolytics Biotech Inc. Completes Patient Enrolment In U.S. Phase 2 Sarcoma Study For The Trial REO 014 113

Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 115
Disclaimer 115

List of Table


Number of Products Under Development for Osteosarcoma, H2 2012 11
Products under Development for Osteosarcoma Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Investigation by Universities/Institutes, H2 2012 16
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 17
Comparative Analysis by Late Stage Development, H2 2012 18
Comparative Analysis by Mid Clinical Stage Development, H2 2012 19
Comparative Analysis by Early Clinical Stage Development, H2 2012 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 21
Products under Development by Companies, H2 2012 22
Products under Investigation by Universities/Institutes, H2 2012 23
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 24
Merck & Co., Inc., H2 2012 25
ZIOPHARM Oncology, Inc., H2 2012 26
Advaxis, Inc., H2 2012 27
Oncolytics Biotech Inc., H2 2012 28
Simcere Pharmaceutical Group, H2 2012 29
Med Discovery SA, H2 2012 30
Hawthorn Pharmaceuticals, Inc., H2 2012 31
Epeius Biotechnologies Corporation, H2 2012 32
Assessment by Monotherapy Products, H2 2012 33
Assessment by Combination Products, H2 2012 34
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Stage and Molecule Type, H2 2012 39
Osteosarcoma Therapeutics Drug Profile Updates 103
Osteosarcoma Therapeutics Discontinued Products 108
Osteosarcoma Therapeutics Dormant Products 109
Osteosarcoma Therapeutics Dormant Products (Contd..1) 110
Osteosarcoma Therapeutics Dormant Products (Contd..2) 111

List of Chart


Number of Products under Development for Osteosarcoma, H2 2012 11
Products under Development for Osteosarcoma Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 15
Late Stage Products, H2 2012 18
Mid Clinical Stage Products, H2 2012 19
Early Clinical Stage Products, H2 2012 20
Discovery and Pre-Clinical Stage Products, H2 2012 21
Assessment by Monotherapy Products, H2 2012 33
Assessment by Combination Products, H2 2012 34
Assessment by Route of Administration, H2 2012 35
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Molecule Type, H2 2012 37
Assessment by Stage and Molecule Type, H2 2012 38

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *